Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03750240 · ClinicalTrials.gov registry record · NA
Metabolic Sodium MRI to Assess Early Response of Breast Cancer to Neoadjuvant Chemotherapy
A NA study, sponsored by NYU Langone Health.
- Terminated
- Registry status
- NA
- Development phase
- 2
- Enrollment target
NCT03750240: Clinical Trial NA study, sponsored by NYU Langone Health.
NCT03750240 is a NA study that was terminated before completion, run by NYU Langone Health. The registered enrollment target is 2 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03750240, a NA study, was terminated before completion, sponsored by NYU Langone Health.
- TERMINATED
- Registry status
- NA
- Development phase
- 2 participants
- Enrollment target
Study Summary
Neoadjuvant chemotherapy (NACT) is administered to treat invasive breast cancer before surgery. It offers the opportunity to evaluate tumor response to treatment in aggressive disease, and guide additional therapies for patients with inadequate response, if detected early. Investigators propose to develop a sodium breast MRI technique that will allow to assess the early metabolic response of breast cancer to NACT, occurring before late structural changes can be detected with standard MRI. This study will scan 12 patients using 1H/23Na MRI at 7 T and DCE MRI with triple-negative breast cancer undergoing AC-T therapy (2 months of Adriamycin + Cyclophosphamide, then 3 months of Taxol): at baseline (pre-NACT); after the first AC cycle (2 weeks); after AC treatment (2 months); after complete NACT (5 months, pre-surgery).
Primary Outcome
Dynamic contrast-enhanced MRI will be used to measure tumor size before and after treatment.
Interventions
- DIAGNOSTIC_TEST Sodium (Na) Magnetic Resonance Imaging (MRI)
- DIAGNOSTIC_TEST Dynamic Contrast- Enhanced (DCE) MRI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2017-07-25 |
| Est. Completion | 2021-06-24 |
| Phase | NA |
Why NCT03750240 stopped before completion
NCT03750240 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 2 interventions - of which Sodium (Na) Magnetic Resonance Imaging (MRI) is the first listed.
NCT03750240 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03750240 about?
NCT03750240 is a clinical study titled "Metabolic Sodium MRI to Assess Early Response of Breast Cancer to Neoadjuvant Chemotherapy". Neoadjuvant chemotherapy (NACT) is administered to treat invasive breast cancer before surgery. It offers the opportunity to evaluate tumor response to treatment in aggressive disease, and guide additional therapies for patients with inadequate response, if detected early. Investigators propose to d...
What is the current status of trial NCT03750240?
This trial is currently terminated. It is a NA study. The enrollment target is 2 participants. The study started on 2017-07-25. Estimated completion is 2021-06-24.
What interventions are being tested in trial NCT03750240?
The interventions under investigation include: Sodium (Na) Magnetic Resonance Imaging (MRI) (DIAGNOSTIC_TEST), Dynamic Contrast- Enhanced (DCE) MRI (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03750240?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03750240's enrollment target sits among peer trials
2 1997th of 2000 the lowest of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI